Olga Militano

761 total citations
42 papers, 446 citations indexed

About

Olga Militano is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Olga Militano has authored 42 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 18 papers in Public Health, Environmental and Occupational Health and 11 papers in Oncology. Recurrent topics in Olga Militano's work include Hematopoietic Stem Cell Transplantation (22 papers), Acute Lymphoblastic Leukemia research (18 papers) and Acute Myeloid Leukemia Research (10 papers). Olga Militano is often cited by papers focused on Hematopoietic Stem Cell Transplantation (22 papers), Acute Lymphoblastic Leukemia research (18 papers) and Acute Myeloid Leukemia Research (10 papers). Olga Militano collaborates with scholars based in United States, Canada and Belgium. Olga Militano's co-authors include Mitchell S. Cairo, Carmella van de Ven, Monica Bhatia, James H. Garvin, Prakash Satwani, Erin Cooney, M.B. Bradley, Ifeyinwa Osunkwo, K. Wolownik and Diane George and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Olga Militano

40 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olga Militano United States	12	247	176	134	78	65	42	446
Sandeep Nagra United Kingdom	13	351 1.4×	143 0.8×	108 0.8×	32 0.4×	45 0.7×	21	518
Albert Esquirol Spain	13	297 1.2×	199 1.1×	81 0.6×	22 0.3×	62 1.0×	45	433
SJ Forman United States	8	413 1.7×	116 0.7×	121 0.9×	66 0.8×	32 0.5×	8	517
Michael Gratwohl Switzerland	8	398 1.6×	134 0.8×	144 1.1×	73 0.9×	19 0.3×	9	521
Josep Sarrà Spain	12	529 2.1×	144 0.8×	297 2.2×	49 0.6×	57 0.9×	25	623
Steve Andresen United States	12	289 1.2×	183 1.0×	64 0.5×	57 0.7×	36 0.6×	30	524
Sergey N. Bondarenko Russia	9	335 1.4×	112 0.6×	132 1.0×	38 0.5×	27 0.4×	117	466
Sinem Civriz Bozdağ Türkiye	10	214 0.9×	114 0.6×	63 0.5×	27 0.3×	38 0.6×	61	397
Rayaz Ahmed India	12	286 1.2×	104 0.6×	110 0.8×	53 0.7×	44 0.7×	55	459
Nan Young Lee South Korea	14	306 1.2×	174 1.0×	64 0.5×	37 0.5×	56 0.9×	41	545

Countries citing papers authored by Olga Militano

Since Specialization

Citations

This map shows the geographic impact of Olga Militano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Militano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Militano more than expected).

Fields of papers citing papers by Olga Militano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Militano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Militano. The network helps show where Olga Militano may publish in the future.

Co-authorship network of co-authors of Olga Militano

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Militano. A scholar is included among the top collaborators of Olga Militano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Militano. Olga Militano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wedekind, Mary Frances, Srivandana Akshintala, Brigitte C. Widemann, et al.. (2023). Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS10066–TPS10066. 1 indexed citations

Militano, Olga, et al.. (2023). Methotrexate Scarcity Among Children’s Oncology Group Institutions: Results of a Multinational Survey. The Oncologist. 30(8). 4 indexed citations

McNeer, Jennifer L., Maureen M. O’Brien, Susan R. Rheingold, et al.. (2021). A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. Blood. 138(Supplement 1). 3398–3398. 8 indexed citations

Militano, Olga, et al.. (2018). Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients. Pediatric Blood & Cancer. 65(8). e27091–e27091. 4 indexed citations

Bhatia, Monica, Erin Morris, Lauren Harrison, et al.. (2016). A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 22(4). 698–704. 21 indexed citations

Pulsipher, Michael A., Qiuhu Shi, Roger Giller, et al.. (2015). A pilot trial of unmatched human placental derived stem cells (HPDSC) infusion in conjunction with unrelated cord blood transplantation (UCBT) in children and young adults with malignant and non-malignant diseases. Cytotherapy. 17(6). S64–S65. 1 indexed citations

McCune, Jeannine S., et al.. (2014). Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics. Bone Marrow Transplantation. 50(2). 165–172. 12 indexed citations

Talano, Julie‐An, Heather J. Symons, Olga Militano, et al.. (2014). New frontiers in pediatric Allo-SCT. Bone Marrow Transplantation. 49(9). 1139–1145. 4 indexed citations

Militano, Olga, Monica Bhatia, Zhezhen Jin, et al.. (2009). Pharmacokinetics (PK) Of IV And Po Mycophenolate Mofetil (MMF) In Age Adjusted Pediatric And Adolescent Allogeneic Stem Cell Transplant (AlloSCT) Recipients: Significantly Higher CLss AND Vss IN PATIENTS <6 YEARS OF AGE. Biology of Blood and Marrow Transplantation. 15(2). 132–133.

10.

Bhatia, Monica, Olga Militano, Zhezhen Jin, et al.. (2009). An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation. 16(3). 333–343. 52 indexed citations

11.

Waxman, Ian M., Olga Militano, Erin Morris, et al.. (2008). Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning^†. Pediatric Transplantation. 13(4). 464–474. 18 indexed citations

12.

Bhatia, Monica, et al.. (2008). 205: Low Molecular Weight Heparin (LMWH) Prophylaxis (PPX) in Pediatric Recipients following Pediatric Myeloablative Stem Cell Transplant (SCT) at High Risk for Sinusoidal Obstructive Syndrome (SOS): Is it Safe and Does it Make a Difference?. Biology of Blood and Marrow Transplantation. 14(2). 76–76. 1 indexed citations

13.

Yamashiro, Darrell J., Monica Bhatia, Julia Glade Bender, et al.. (2007). 185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma. Biology of Blood and Marrow Transplantation. 13(2). 68–69. 6 indexed citations

14.

Militano, Olga, Leslie M. Shaw, Michal Figurski, et al.. (2007). 315: Pharmacokinetics (PK) of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (AlloSCT) recipients. Biology of Blood and Marrow Transplantation. 13(2). 114–115. 1 indexed citations

15.

Roman, Eve, Erin Cooney, Olga Militano, et al.. (2007). 76: Reduced intenity allogeneic stem cell transplantion followed by targeted consolidation immunotherapy with gemtuzumab ozogamicin in children and adolescents with CD33+ acute myeloid leukemia. Biology of Blood and Marrow Transplantation. 13(2). 30–31. 2 indexed citations

16.

Bradley, M.B., Prakash Satwani, Erin Morris, et al.. (2007). Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplantation. 40(7). 621–631. 60 indexed citations

17.

Osunkwo, Ifeyinwa, et al.. (2007). Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatric Blood & Cancer. 50(2). 325–330. 52 indexed citations

18.

Militano, Olga, G. Del Toro, Prakash Satwani, et al.. (2006). Sequential administration of sargramostim (GM-CSF) and filgrastim (G-CSF) in pediatric allogeneic stem cell transplant (allosct) recipients undergoing myeloablative (MA) conditioning: Cost-effective and more rapid platelet recovery in UCB recipients. Biology of Blood and Marrow Transplantation. 12(2). 43–43. 2 indexed citations

19.

Angiolillo, Anne, Virginia Davenport, Mary Ann Bonilla, et al.. (2005). A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience. Clinical Cancer Research. 11(7). 2644–2650. 14 indexed citations

20.

Bradley, M.B., Lauren Harrison, Erin Cooney, et al.. (2004). Reduced Intensity (RI) Allogeneic Stem Cell Transplantation (ALLOSCT) with Umbilical Cord Blood (UCB) in Pediatric Patients with Malignant and Non-Malignant Diseases.. Blood. 104(11). 5167–5167. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact